• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

DepoDur (morphine sulfate extended-release) liposome injection

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- September 2009

 

Summary View

 

PRECAUTIONS 

General
  • revised to include statement to reinforce that DepoDur dosing will need to be adjusted in the elderly and other risk groups taking into account the patient's age, body mass, physical status, prior experience with opiate analgesics, risk factors for respiratory depression, and medications to be co-administered before or during surgery

CLINICAL PHARMACOLOGY

Drug Interactions
  • revised to include pharmacokinetic interaction with respect to DepoDur and therapeutic doses of local anesthetic bupivacaine HCI